June 22, 2026 02:34 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Italy and I never beg': Meloni fires back at Trump over G7 photo claim | No more 'brother': Stalin's formal birthday greeting to Rahul reflects deepening rift | TMC seeks disqualification of 20 rebel MPs, Abhishek says 'membership should go' | Nara Lokesh pitches Andhra Pradesh as investment hub during Kolkata visit, sets $2.4 trillion economy goal | 'Least restrictive option': Setback for Telegram as Delhi HC backs Centre's ban ahead of NEET-UG re-test | Fortuner torched, BJP leaders burnt alive: Sand mining feud ends in triple murder in Chhattisgarh | 'If Modi is the leader and India is attacked, we'll be there': Trump's strong assurance at G7 | 'Safety of Indian seafarers of utmost importance': PM Modi's strong message to Trump at G7 | Trump says Iran deal 'not final', threatens fresh strikes if Tehran ‘doesn’t behave’ | G7 declares war on global drug cartels, unveils major anti-trafficking plan
Johnson Baby Powder
Image Credit: wikipedia.org

Maharashtra FDA cancels Johnson & Johnson baby powder licence

| @indiablooms | Sep 18, 2022, at 05:06 am

Mumbai: The Maharashtra FDA has cancelled the baby talcum powder manufacturing licence of Johnson & Johnson, Mulund, after the department found it "Not Of Standard Quality".

The FDA said that the licence was cancelled after samples of the Johnson’s Baby Powder collected from Nashik and Pune failed quality checks and ordered the company to recall all its stocks from the markets.

These samples were declared by the FDA as ‘Not Of Standard Quality’ after they failed to comply with IS5339:2009 (Second Revision Amendment No. 3) Specification for Skin Powder for infants in the test pH.

In a statement, the FDA said: “The product Johnsons Baby Powder is popularly used in newborn babies. The sample declared 'Not of Standard' in pH and the use of the product may affect the health of the skin of the newborn babies.”

The firm "didn't accept the report" and challenged it in court for sending it to the Central Drugs Laboratory, the FDA said, according to media reports.

(With UNI inputs)

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.